Literature DB >> 16000329

Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation.

Carolin Feterowski1, Alexander Novotny, Simone Kaiser-Moore, Peter F Mühlradt, Tanja Rossmann-Bloeck, Martina Rump, Bernhard Holzmann, Heike Weighardt.   

Abstract

The innate immune system uses Toll-like receptors (TLRs) to activate and instruct immune responses against microbial pathogens. Administration of TLR agonists to mice induces a state of hyporesponsiveness, or tolerance, characterized by reduced cytokine production upon subsequent second challenge. The present study examined the effects of pre-treatment of mice with TLR2-dependent stimuli on the host defense against acute polymicrobial infection. Immune priming of mice with macrophage-activating lipopeptide-2 (MALP-2) 4 days prior to infection greatly improves survival and bacterial clearance in a model of polymicrobial septic peritonitis which is associated with enhanced accumulation of effector neutrophils in the peritoneal cavity. Further, the systemic and local production of both myeloid differentiation factor 88 (MyD88)-dependently and MyD88-independently produced cytokines was substantially diminished, but not completely absent, in TLR2-treated mice. While pre-treatment with MALP-2 does not involve differential expression of TLR and IL-1R-associated kinase proteins, ST2, a negative regulator of TLR signaling, was up-regulated after treatment of mice with either MALP-2 or N-alpha-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-L-cysteine. Therefore, ST2 may be a mechanism, among others, to attenuate the sepsis-induced cytokine burst. Thus, these results suggest that immune protection in mice after pre-treatment with TLR2-dependent stimuli involves the induction of enhanced pathogen defense by neutrophils. In addition, up-regulation of ST2 could contribute to the diminished cytokine production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000329     DOI: 10.1093/intimm/dxh282

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  18 in total

1.  Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus.

Authors:  Travis Kochan; Anuj Singla; Joaquin Tosi; Ashok Kumar
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

2.  Poly(I:C) Priming Exacerbates Cecal Ligation and Puncture-Induced Polymicrobial Sepsis in Mice.

Authors:  Deepika Sharma; Ankit Malik; Nandakumar Packiriswamy; Michael D Steury; Narayanan Parameswaran
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

3.  Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis.

Authors:  Ashok Kumar; Christopher N Singh; Inna V Glybina; Tamer H Mahmoud; Fu-Shin X Yu
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

4.  Increased inflammation and lethality of Dusp1-/- mice in polymicrobial peritonitis models.

Authors:  Michael Hammer; Bernd Echtenachter; Heike Weighardt; Katrin Jozefowski; Stefan Rose-John; Daniela N Männel; Bernhard Holzmann; Roland Lang
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

5.  IL-33 Treatment Attenuates the Systemic Inflammation Reaction in Acinetobacter baumannii Pneumonia by Suppressing TLR4/NF-κB Signaling.

Authors:  Chunhong Peng; Jin Han; Xianwei Ye; Xiangyan Zhang
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

6.  Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis.

Authors:  Georg F Weber; Sylvia Schlautkötter; Simone Kaiser-Moore; Felicitas Altmayr; Bernhard Holzmann; Heike Weighardt
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

7.  Organ-specific role of MyD88 for gene regulation during polymicrobial peritonitis.

Authors:  Heike Weighardt; Jörg Mages; Gabriela Jusek; Simone Kaiser-Moore; Roland Lang; Bernhard Holzmann
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

Review 8.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

Review 9.  Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.

Authors:  J L Wynn; J Neu; L L Moldawer; O Levy
Journal:  J Perinatol       Date:  2008-09-04       Impact factor: 2.521

10.  Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists.

Authors:  James L Wynn; Philip O Scumpia; Robert D Winfield; Matthew J Delano; Kindra Kelly-Scumpia; Tolga Barker; Ricardo Ungaro; Ofer Levy; Lyle L Moldawer
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.